ORPHA:3325
Classic heparin-induced thrombocytopenia
Also known as: Classic HAT · Classic HIT · Classic heparin-associated thrombocytopenia · HITT · Heparin-induced-immune thrombocytopenia
Publications
12,297
Trials
21
Interventional, condition-specific
Researchers
1,061
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare drug-induced, immune-mediated prothrombotic disorder associated with thrombocytopenia and venous and/or arterial thrombosis.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018048
- UMLS:C0272285
Additional Mondo synonyms (6)
HAT · HIT · heparin-associated thrombocytopenia · heparin-induced thrombocytopenia · heparin-induced thrombocytopenia (disease) · heparin-induced thrombocytopenia type 2
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
12,297 matched papers (7,046 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
21 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
12,297
12,297 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
12,297 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
7,046 in the last 10 years · low confidence
Phrase hits: 12,297 · MeSH hits: 0
Who's working on it?
1,061
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Warkentin TE11 papers · 2026
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada; Transfusion Medicine, Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada; Service of Benign Hematology, Hamilton Health Sciences, Hamilton General Hospital, Hamilton, ON, Canada; McMaster Center for Transfusion Research, McMaster University, Hamilton, ON, Canada. Electronic address: twarken@mcmaster.ca.
Papers in Europe PMC - 02Nazy I9 papers · 2026
Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada; Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada. Electronic address: nazyi@mcmaster.ca.
Papers in Europe PMC - 03Zhang Y7 papers · 2026
Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada; Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
Papers in Europe PMC - 04Arnold DM6 papers · 2026
Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada; Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.
Papers in Europe PMC - 05Greinacher A6 papers · 2026
Institut für Transfusionsmedizin, Universitätsmedizin Greifswald, 17487, Greifswald, Deutschland.
Papers in Europe PMC - 06Hashemzadeh M6 papers · 2026
University of Arizona College of Medicine, 6119 North Pinchot, Phoenix, AZ, 85750, USA. mhashemz1@yahoo.com.
Papers in Europe PMC - 07Bakchoul T5 papers · 2026
Institute for Clinical and Experimental Transfusion Medicine, University Hospital of Tübingen, Tübingen, Germany; Centre for Clinical Transfusion Medicine, University Hospital Tübingen, Tübingen, Germany. Electronic address: tamam.bakchoul@med.uni-tuebingen.de.
Papers in Europe PMC - 08Padmanabhan A5 papers · 2026
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: padmanabhan.anand@mayo.edu.
Papers in Europe PMC - 09Wang D5 papers · 2026
Versiti Blood Research Institute, Milwaukee, Wisconsin, United States.
Papers in Europe PMC - 10Althaus K4 papers · 2026
Institute for Clinical and Experimental Transfusion Medicine, University Hospital of Tübingen, Tübingen, Germany; Centre for Clinical Transfusion Medicine, University Hospital Tübingen, Tübingen, Germany.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
21
interventional trials for this specific condition
21 interventional trials matched this specific condition name; 1 currently recruiting in our sample.
Data as of 27 July 2026
21 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 94.7th percentile).
low confidence · 94.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
21 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06033300·RECRUITING·Characterization and Quantification of Platelet/Leukocyte Aggregates in Patients With Suspected Heparin-induced Thrombocytopenia
Conditions: Heparin-induced Thrombocytopenia · HIT · Platelet Activation · Platelets·Matched via name phrase
Observational and natural-history studies
22 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT02717039·RECRUITING·Pharmacogenomics of Heparin-Induced Thrombocytopenia
Conditions: Heparin-induced Thrombocytopenia·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Classic heparin-induced thrombocytopenia" OR "Classic HAT" OR "Classic HIT" OR "Classic heparin-associated thrombocytopenia" OR "Heparin-induced-immune thrombocytopenia" OR "heparin-associated thrombocytopenia" OR "heparin-induced thrombocytopenia" OR "heparin-induced thrombocytopenia (disease)" OR "heparin-induced thrombocytopenia type 2"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Classic heparin-induced thrombocytopenia" OR "Classic HAT" OR "Classic HIT" OR "Classic heparin-associated thrombocytopenia" OR "Heparin-induced-immune thrombocytopenia" OR "heparin-associated thrombocytopenia" OR "heparin-induced thrombocytopenia" OR "heparin-induced thrombocytopenia (disease)" OR "heparin-induced thrombocytopenia type 2"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 21 interventional · 22 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: HITT; HAT; HIT
Confidence reasoning
- Preferred label is multi-word and distinctive
- 3 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (12297) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T22:53:02.523Z